Menin-MLL inhibitor-22
Product Specifications
UNSPSC Description
Menin-MLL inhibitor-22 (compound C20) is an orally active inhibitor of the interaction between menin and mixed lineage leukemia (MLL) (IC50=7 nM). Menin-MLL inhibitor-22 binds menin protein and inhibits cancer cell growth (MV4 cells, IC50=0.3 μM). Menin is a putative tumor suppressor associated with multiple endocrine neoplasia type 1 (MEN-1 syndrome)[1].
Target Antigen
Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/menin-mll-inhibitor-22.html
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=S(C1=CC=C(N2CC(CN3CCC(NC4=NC=NC5=CC=C(N=C54)OCCN(C)C)CC3)C2)C=C1)(C6CC6)=O
Molecular Weight
565.73
References & Citations
[1]Lei H, et al. Discovery of Novel, Potent, and Selective Small-Molecule Menin-Mixed Lineage Leukemia Interaction Inhibitors through Attempting Introduction of Hydrophilic Groups. J Med Chem. 2022 Oct 13;65(19):13413-13435.
Shipping Conditions
Blue Ice
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-151595/Menin-MLL-inhibitor-22-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-151595/Menin-MLL-inhibitor-22-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
2851841-61-5
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
